Skip to main content
FDA panel votes against empagliflozin as insulin add-on in T1D
11/15/2019

An FDA advisory panel voted against the use of empagliflozin, an SGLT2 inhibitor, as an adjunct to insulin therapy in patients with type 1 diabetes. The potential risk of diabetic ketoacidosis with higher doses led the panel to say that the data did not show that the treatment's benefits outweigh the risks and an additional study is needed.

Full Story: